Live Biotherapeutics as cancer treatments: scientific and regulatory challenges

Staff editor

20.09.2023

Jean-Luc Marsat, CEO & Chairman at EverImmune, discusses the research EverImmune carries out in oncology.

During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiomepost sat down with Jean-Luc Marsat, CEO & Chairman at EverImmune, to discuss the research EverImmune carries out in oncology.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

Read MicrobiomePost’s Privacy Policy

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.

Live Biotherapeutics as cancer treatments: scientific and regulatory challenges

Latest related content

NIST redefines gut microbiome research with breakthrough reference material

Gut microbes linked to inflammatory bowel diseases worsen colitis in mice

Sugary drinks may raise diabetes risk by altering gut bacteria

MaaT013 cleared for pediatric trials: EMA approval marks key milestone for microbiome therapy in aGvHD

Resetting the immune system: HMOs as a promising treatment for Gut-Brain Axis disorders

Bloom Science’s Live Biotherapeutic BL-001 achieves significant weight loss in Phase 1 trial

Latest News